U.S. FDA Turns To Indian Pharma Firms Amid Cancer Drug Shortage; Cipla, Zydus In Focus

Indian pharmaceutical companies are in focus after reports indicated that the U.S. FDA has reached out to India to help address a shortage of Ifosfamide, a critical chemotherapy drug used in the treatment of multiple cancers. The shortage follows manufacturing disruptions and supply chain challenges in the United States, creating a potential opportunity for Indian drugmakers. Companies such as Cipla, Zydus Lifesciences, Alkem and Piramal could benefit due to their manufacturing capabilities and experience in regulated markets. While no supply contracts have been confirmed yet, the development reinforces India's position as a key global supplier of essential medicines.